Management of Daily Spotting Four Months After Nexplanon Insertion
Reassure the patient that daily spotting at four months is common and not harmful, then initiate mefenamic acid 500 mg three times daily for 5 days during bleeding episodes as first-line treatment. 1
Understanding the Clinical Context
Daily spotting at four months post-insertion falls within the expected timeframe for Nexplanon-related bleeding irregularities, which are most common during the first 3–6 months of use. 2 Approximately 18% of users experience prolonged bleeding and 7% report frequent bleeding episodes during the first year. 1 These bleeding patterns are generally not harmful and do not indicate contraceptive failure. 1
The bleeding pattern experienced during the first three months broadly predicts future patterns for many women, though individual variation is high. 3 About 75% of women who have favorable bleeding patterns initially continue with this pattern, while those with unfavorable initial patterns have at least a 50% chance of improvement. 3
Initial Evaluation Before Treatment
Before attributing the bleeding solely to Nexplanon, systematically exclude other causes:
- Rule out pregnancy first as the initial step in any evaluation of abnormal bleeding. 1
- Screen for sexually transmitted infections, as these can cause irregular bleeding patterns in both adolescents and adults. 1
- Review all concomitant medications for potential drug interactions that may affect bleeding patterns, including antibiotics and anticonvulsants. 1
- Evaluate for new uterine pathology such as polyps, fibroids, or structural abnormalities through appropriate imaging if clinically indicated. 1
First-Line Pharmacologic Management
Mefenamic acid 500 mg three times daily for 5 days during bleeding episodes is the recommended first-line therapy, achieving significant bleeding cessation within 7 days compared with placebo. 1 This NSAID-based approach is the most effective initial pharmacologic intervention. 1
Celecoxib 200 mg once daily for 5 days serves as an alternative NSAID option that also demonstrates efficacy in reducing bleeding duration. 1
Avoid ibuprofen as a primary option because it shows inconsistent results—one study reported reduction in bleeding days while another found no significant difference versus placebo. 1
Second-Line Hormonal Management
If NSAIDs fail or are contraindicated, escalate to hormonal therapy:
Low-dose combined oral contraceptives for 10–20 days during bleeding episodes are highly effective, with 76.2% of women achieving bleeding cessation within 7 days compared with only 35.7% when treated with NSAIDs. 4, 1 This represents a statistically significant improvement. 4
Estrogen-only therapy for 10–20 days can reduce the number of bleeding days in women who cannot use combined oral contraceptives, but cardiovascular contraindications must be screened for beforehand. 1
Treatments to Avoid
Do not use doxycycline alone, as it does not improve bleeding cessation in implant users and should not be used as a sole intervention. 1
Aspirin offers no therapeutic advantage and showed no significant difference in the median length of bleeding episodes. 1
When to Consider Alternative Contraception
If bleeding persists despite pharmacologic treatment and the patient finds it unacceptable, counsel her on alternative contraceptive methods and offer to switch. 2, 1
The levonorgestrel-releasing intrauterine system (20 µg/day) is the most effective alternative, reducing menstrual blood loss by 71–95%. 1 This may be the optimal choice for women with refractory bleeding who desire long-term contraception.
More than half of adolescent implant users discontinue before 24 months, with abnormal bleeding being the most common reason. 1 Enhanced counseling about expected bleeding patterns and available treatments reduces discontinuation rates. 1
Critical Safety Considerations
- Do not prescribe estrogen without first assessing cardiovascular contraindications, especially history of spontaneous coronary artery dissection. 1
- Avoid tranexamic acid in patients with cardiovascular risk factors due to its association with thrombotic events. 1
Common Pitfalls
The most critical error is assuming all bleeding is benign without excluding pregnancy, STIs, and structural pathology first. 1 Always complete the initial evaluation before initiating treatment.
Another pitfall is failing to provide adequate counseling about the unpredictable nature of bleeding patterns with Nexplanon—effective pre-insertion and ongoing counseling improves continuation rates. 3, 1